

ECNP Supports European Research Projects



Autism Innovative Medicine Studies – 2 – Trials

Exploring the biology of autism and developing new medicines tailored to individual needs

THE CHALLENGE Around 5.5 million people in Europe have autism. Approximately 70% of autistic people also have co-occurring conditions, such as anxiety, depression or epilepsy. It has been difficult to develop treatments for autism and these co-occurring conditions because autism is incredibly diverse, varying between people and across different stages of life.



THE GOAL AIMS-2-TRIALS (Autism Innovative Medicine Studies – 2 – Trials) is a research programme that will explore the biology of autism to develop new medicines tailored to individual needs.



THE PLAN & THE IMPACT AIMS-2-TRIALS wants to put Europe at the forefront of autism research

- The project will research how autism develops, from before birth to adulthood, and how this varies in people.
- It will identify biological markers and test medicine to help with social difficulties, repetitive behaviours and sensory processing.
- To accelerate medicine development, AIMS-2-TRIALS will build a network to connect researchers, clinicians and the autism community.
- It will also explore policies to better support autistic people and develop educational tools to improve the understanding of autism.



Project co-ordinator: **Declan Murphy**, King's College London
 Project Lead: **Will Spooren**, Roche
 Term: 1 June 2018 - 31 May 2023
 Website: <https://www.aims-2-trials.eu>



The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777394. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI.

